Multiprong Strategy Makes Clinical Trials Less White

Clinical trials for cancer control and treatment typically have very few patients from non-White backgrounds, but a multipronged approached has increased participation of underrepresented patients.

Related Keywords

Memorial Sloan Kettering Cancer Center ,New York ,United States ,Chicago ,Illinois ,American ,Monicam Bertagnolli ,Electrad Paskett , ,American Society Of Clinical Oncology ,Alliance For Clinical Trials In Oncology ,National Cancer Institute Community Oncology Research Program ,Program To Increase Underrepresented Patient Accrual ,Ohio State University In Columbus ,Us National Cancer Institute ,College Of Public Health ,Drug Administration ,American Society ,Clinical Oncology ,Clinical Trials ,Public Health ,Ohio State University ,Increase Underrepresented Patient Accrual ,Medscape Medical ,New York City ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Clinical Research ,Linical Studies ,Cancer ,Alignant Neoplasia ,Arcinoma ,Social Determinants Of Health ,Adolescent Medicine ,Health Care Inequity ,Ohio ,Pandemic ,Professional Development ,Leadership ,Rural Health ,Ural Medicine ,Young Adult ,